Satoshi Ikeda

30PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Aug 07, 2026
Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan.

|May 22, 2026
Survival, toxicity, and sequencing: navigating the new first-line standard established by FLAURA2.

|Jan 28, 2026
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology.

Satoshi Ikeda, Keigo Araki, Mai Kitagawa

|Oct 29, 2025
Cemiplimab in Japanese patients with advanced non-small cell lung cancer.

Yuki Sato, Yoko Tani, Hidenobu Ishii

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

|Mar 08, 2025
High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study.

Yuriko Ishida, Satoshi Ikeda, Toshiyuki Harada

Pageof 5

Frequent Collaborators

4 joint publications

Toshihiro Misumi

3 joint publications

Naoki Furuya

2 joint publications

Yoshimasa Shiraishi

2 joint publications

Yuki Sato